Peter Hunt

Professor and Co-Director of Basic/Translational Sciences, Center for AIDS Research

Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine (DEM) at the University of California San Francisco. He also serves as Co-Director of the UCSF-GIVI Center for AIDS Research (for basic and translational science) and as a member of the Leadership Committee of the UCSF AIDS Research Institute. He also recently completed terms as Interim Chief of the DEM and Chair of the ACTG Inflammation and End Organ Disease Transformative Science Group. His primary research focus is on the inflammatory consequences of HIV infection. His clinic-based translational research program seeks to understand the determinants of persistent immune activation both in the presence and the absence of antiretroviral therapy, and to assess the impact of immune activation on clinical outcomes. He collaborates extensively with a multi-disciplinary team of investigators to assess the impact of persistent immune activation despite viral suppression on mortality and chronic diseases associated with aging (i.e., cardiovascular disease) and conducts clinical trials of novel immune-based interventions designed to decrease immune activation. Dr. Hunt has also led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting. He also helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. In 2016, he started a laboratory in the DEM, focused on the immunologic consequences of asymptomatic CMV replication during treated HIV infection as well as the adaptive immune defects that persist in this setting in an effort to develop targets for interventions to reduce morbidity and mortality.
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Infectious Diseases Fellowship, 2005 - Medicine, University of California, San Francisco
General Internal Medicine Fellowship, 2003 - Medicine, University of California, San Francisco
Residency, 2001 - Internal Medicine, University of California, San Francisco
M.D., 1998 - School of Medicine, Yale University
B.A., 1994 - Biology, Yale University
Honors and Awards
  • AIDS Research Institute Teaching and Mentoring Award, UCSF, 2015
  • Emerging Leader in HIV Research Award, HIVMA, 2010
  1. Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection.
  2. Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS).
  3. Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Post-Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight.
  4. Association of Gut Intestinal Integrity and Inflammation with Insulin Resistance in Adults Living with HIV in Uganda.
  5. Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study.
  6. Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the US.
  7. HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia.
  8. Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults.
  9. CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals.
  10. Association of Systemic Inflammation With Retinal Vascular Caliber in Patients With AIDS.
  11. High incidence of intended partner pregnancy among men living with HIV in rural Uganda: Implications for safer conception services.
  12. Increased mucosal neutrophil survival is associated with altered microbiota in HIV infection.
  13. Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy.
  14. Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort.
  15. Participating in HIV Cure Research at the End of Life.
  16. Antiretroviral treatment of acute HIV infection normalizes CSF markers of CNS inflammation. A consequence of reduced CNS reservoir?
  17. Cumulative human immunodeficiency viremia, antiretroviral therapy, and incident myocardial infarction.
  18. Stimulant Use and Viral Suppression In the Era of Universal Antiretroviral Therapy.
  19. Association of age-related macular degeneration with mortality in patients with AIDS; role of systemic inflammation.
  20. Genotypic and Mechanistic Characterization of Subtype-specific HIV Adaptation to Host Cellular Immunity.
  21. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency.
  22. Contraceptive use following unintended pregnancy among Ugandan women living with HIV.
  23. HIV DNA decay during antiretroviral therapy: lessons from a clinic-based cohort study.
  24. Prevalence and correlates of physical and sexual intimate partner violence among women living with HIV in Uganda.
  25. Differentiation of Type 1 and Type 2 Myocardial Infarctions among HIV-infected patients requires adjudication due to overlap in risk factors.
  26. CYP2B6 genetic polymorphisms, depression, and viral suppression in adults living with HIV initiating efavirenz-containing antiretroviral therapy regimens in Uganda: pooled analysis of two prospective studies.
  27. The Clinical-Translational Physician-Scientist: Translating Bedside to Bench.
  28. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.
  29. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.